Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2065-2069

  Gómez, Henry ^a   Hidalgo, Manuel ^a   Casanova, Luis ^a   Colomer, Ramon ^a   Pen, Daniel Lee ^a   Otero, Jorge ^a   Rodríguez, Wuilbert ^a   Carracedo, Carlos ^a   Cortés Funes, Hernán ^a   Vallejos, Carlos ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0345451062     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2065     Document Type: Article

References (29)

1. Dixon DO, Neilan B, Jones SE, et al: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group Experience. J Clin Oncol 4:295-305, 1986
2. Vose J, Armitage JO, Weisenburger DD, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838-1844, 1991
3. Armitage JO, Potter JF: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. Increased complications with advancing age. J Am Geriatr Soc 32:269-273, 1984
4. Begg CB, Carbone PP: Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52:1986-1992, 1983
5. Chatta GS, Dale CD: Aging and haemapoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging 9:37-47, 1996
6. Shipp MA, Harrington DP, Klatt MM, et al: Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-Bacod or M-BACOD Ann Intern Med 104:757-765, 1986
7. Cowan RA, Jones M, Harris M, et al: Prognostic factors in high- and intermediate-grade non-Hodgkin's lymphoma. Br J Cancer 61:276-282, 1989
8. Velasquez WS, Jagannath S, Tucker SL, et al: Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 74:551-557, 1989
9. Coiffier B, Gisselbrecht C, Vose JM, et al: Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Aggresifs. J Clin Oncol 9:211-219, 1991
10. Hayward RL, Leonard RCF, Prescott RI, with the members of the Scotland and Newcastle Lymphoma Group Therapy Working Party: A critical analysis of prognostic factors for survival in intermediate- and high-grade NHL. Br J Cancer 63:945-952, 1991
11. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
12. National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphoma: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
13. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxyldaunomycin (Adriamicin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976
14. Jagannath S, Velasquez WS, Tucker SL, et al: Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 4:859-865, 1986
15. Hryniuk WM, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
16. Hoskins PJ, Ng V, Spinelli JJ, et al: Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 9:220-226, 1991
17. Coiffier B, Giosselbrecht C, Herbrecht R, et al: LNH-84 Regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
18. Kimmick GG, Fleming R, Muss HB, et al: Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging 10:34-49, 1997
19. Tirelli U, Zagonel V, Serraino D, et al: Non-Hodgkin's lymphoma in 137 patients aged 70 years or older: A retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study. J Clin Oncol 6:1708-1713, 1988
20. Tirelli U, Van Glabbeke M, Teodorovic I, et al: A randomized comparison of CHOP vs a new combination of VP-16, mitoxantrone and premustine (VMP) > 70 years of age with intermediate to high-grade NHL: An EORTC Lymphoma Group Study. Proc Am Soc Clin Oncol 14:398, 1995 (abstr 1250)
21. Coiffier B, Biron P, Bastion Y, et al: Elderly lymphoma patients have a long survival if treated with a curative intent. A study from the GELA on 435 patients older than 69 years. Proc Am Soc Clin Oncol 15:417, 1996 (abstr 1279)
22. Komaki R, Pajak TF, Byhardt RW, et al: Analysis of early and late deaths on RTOG non-small-cell carcinoma of the lung trials: Comparison with CALGB 8433. Lung Cancer 10:189-197, 1993
23. Valls A, Algara M, Marrugat J, et al: Risk factors for early mortality in allogeneic bone marrow transplantation. A multivariate analysis on 174 leukemia patients. Eur J Cancer 29A: 1523-1528, 1993
24. Morittu L, Earl HM, Souhami RL, et al: Patients at risk of chemotherapy-associated toxicity in small-cell lung cancer. Br J Cancer 59:801-805, 1989
25. Garaventa A, Porta F, Rondelli R, et al: Early deaths in children after BMT. Bone Marrow Transplant 10:419-423, 1992
26. Frasci G, Perillo G, Comella G, et al: Phase I/II study of carboplatin and oral etoposide with granulocyte colony-stimulating factor in advanced non-small-cell lung cancer. Cancer 75:1578-1585, 1995
27. Leibovivi L, Greenshtain S, Cohen O, et al: Bacteremia in febrile patients. A clinical model for diagnosis. Arch Intern Med 151:1801-1806, 1991
28. Cheson BD: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 15:2431-2448, 1995
29. Rossini F: Prognosis of infections in elderly patients with haematological diseases. Support Care Cancer 4:46-50, 1996